Skip to main content
MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. logo

MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. — Investor Relations & Filings

Ticker · 688062 ISIN · CNE100005RD2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 541 across all filing types
Latest filing 2025-07-23 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 688062

About MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.

https://www.mabwell.com/en/

Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of therapeutic antibodies and innovative biologics. The company maintains an integrated R&D and manufacturing platform covering the full drug lifecycle, from target discovery and preclinical research to clinical development and commercial production. Its therapeutic pipeline addresses critical needs in oncology, autoimmune diseases, metabolic disorders, ophthalmology, and infectious diseases. Mabwell leverages proprietary technology platforms, including antibody-drug conjugates (ADCs), bispecific antibodies, and high-throughput screening, to develop a diverse portfolio of novel drug candidates and biosimilars. The organization is committed to delivering high-quality, accessible therapeutic solutions through its end-to-end biotechnological capabilities.

Recent filings

Filing Released Lang Actions
迈威生物关于以集中竞价交易方式回购股份的回购报告书
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement regarding the company's plan to repurchase its own shares through a centralized bidding process on the Shanghai Stock Exchange. It includes specifics about the repurchase amount, price limits, funding sources, purpose (employee stock ownership plan or equity incentives), authorization details, risk factors, and the impact on the company's financials and shareholding structure. The document is not a financial report, earnings release, or management discussion but a formal report on the share repurchase plan and its implementation. This fits the definition of a Transaction in Own Shares (POS) filing, which covers share buybacks or repurchases by the company. The document length and detail confirm it is the report itself, not just an announcement of a report publication.
2025-07-23 Chinese
北京植德（上海）律师事务所关于迈威（上海）生物科技股份有限公司2025年第一次临时股东大会的法律意见书
Regulatory Filings
2025-07-21 Chinese
迈威生物2025年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an announcement of the resolutions from the 2025 first extraordinary general meeting of shareholders of Maiwei (Shanghai) Biotechnology Co., Ltd. It details the meeting date, attendance, voting results, and legal witness statements. It does not contain financial statements or detailed financial analysis but reports the official voting results of shareholder decisions. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)'. The document length is short (1410 characters) and is clearly a voting result announcement, not a full report or presentation.
2025-07-21 Chinese
迈威生物2025年第一次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as the "2025 First Extraordinary General Meeting (EGM) Meeting Materials" of Maiwei (Shanghai) Biotechnology Co., Ltd. It contains detailed meeting instructions, agenda, and a specific proposal regarding a licensing agreement with CALICO LIFE SCIENCES LLC. The content is focused on the meeting procedures, voting, and the proposal to be discussed and voted on by shareholders. There are no financial statements or quarterly/yearly financial data presented. The document is a set of materials prepared for a shareholders' meeting, specifically an extraordinary general meeting, including the agenda and proposals for shareholder approval. This fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual or Extraordinary General Meeting. The document length is about 5252 characters, which is consistent with a meeting material document rather than a brief announcement or a full report. Therefore, the correct classification is AGM Information (AGM-R).
2025-07-15 Chinese
迈威生物关于回购股份事项前十大股东和前十大无限售条件股东持股情况的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from a company regarding the share repurchase plan and the shareholding details of the top ten shareholders and top ten unrestricted shareholders before the repurchase. It includes specific shareholding numbers and percentages, and references a previous announcement about the share repurchase plan. The document does not contain financial statements or detailed financial analysis but focuses on shareholding and repurchase information. This fits the category of a Transaction in Own Shares (POS) filing, which covers company buybacks or sales of its own shares.
2025-07-03 Chinese
迈威生物关于迈威重庆引入投资人进展的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from the board of directors of Maiwei (Shanghai) Biotech Co., Ltd. regarding the progress of introducing investors into its Chongqing subsidiary. It details the investment agreements, capital increase, and changes in shareholding structure. The content focuses on financing activities, capital contributions, and shareholder structure changes. The document length is 1577 characters, which is relatively short but contains substantive information about capital investment and shareholding changes, not merely a notice or link to a report. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2025-06-30 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.